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Abstract The aims of this study were to evaluate the
frequency of Achromobacter xylosoxidans infection in a
cohort of cystic fibrosis patients, to investigate antimicro-
bial sensitivity, to establish possible clonal likeness among
strains, and to address the clinical impact of this infection
or colonization on the general outcome of these patients.
The study was undertaken between January 2004 and
December 2008 on 300 patients receiving care at the
Regional Cystic Fibrosis Center of the Naples University
“Federico II”. Sputum samples were checked for bacterial
identification. For DNA fingerprinting, pulsed-field gel
electrophoresis (PFGE) was carried out. Fifty-three patients
(17.6%) had at least one positive culture for A. xylosox-
idans; of these, 6/53 (11.3%) patients were defined as
chronically infected and all were co-colonized by Pseudo-
monas aeruginosa. Of the patients, 18.8% persistently
carried multidrug-resistant isolates. Macrorestriction analy-
sis showed the presence of seven major clusters. DNA
fingerprinting also showed a genetic relationship among
strains isolated from the same patients at different times.
The results of DNA fingerprinting indicate evidence of
bacterial clonal likeness among the enrolled infected
patients. We found no significant differences in the forced
expiratory volume in 1 s (FEV1) and body mass index
(BMI) when comparing the case group of A. xylosoxidans
chronically infected patients with the control group of P.
aeruginosa chronically infected patients.
Introduction
Over the past 20 years, the epidemiology of bacteria
involved in acute infections in cystic fibrosis (CF) has
become increasingly complex. Although Pseudomonas
aeruginosa, Staphylococcus aureus,a n dHaemophilus
influenzae have been the most common pathogens in the
lower airways of CF patients, with improved survival, new
emergent pathogens such as Burkholderia cepacia complex
(Bcc), Stenotrophomonas maltophilia, Achromobacter xylo-
soxidans, Aspergillus spp., non-tuberculous mycobacteria,
and respiratory viruses have been detected in the last few
years [1–12]. Other unusual bacteria such as Acinetobacter
spp., Bordetella spp., Moraxella spp., Comamonas spp.,
Rhizobium spp., Herbaspirillum spp., and Inquilinus limo-
sus have recently been described [13], and, also, Italian
studies have reported Gram-negative non-fermentative
bacteria such as Chryseobacterium meningosepticum,
Chryseobacterium indologenes, Chryseobacterium gleum,
Sphingobacterium spiritivorum,a n dSphingobacterium
multivorum in sputum samples of CF patients [14, 15].
Moreover, mycetes such as Scedosporium apiospermum,
Penicillium, and Exophiala have also been recognized [16–
19]. The pathogenic role of several of these microorganisms
has not yet been clarified.
A. xylosoxidans is an aerobic, oxidase- and catalase-
positive, non-lactose fermenting, Gram-negative bacillus
widely distributed in the natural environment. Its taxonomic
position has been considered to be uncertain during the last
decades: the genus was named Achromobacter,t h e n
Alcaligenes, and then again Achromobacter. The phyloge-
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than 10% in the GC content of DNA, demonstrated that A.
xylosoxidans and Alcaligenes faecalis (type species of the
genus Alcaligenes) belong to two distinct genera, Achro-
mobacter and Alcaligenes, respectively [20].
A. xylosoxidans is an opportunistic human pathogen
capable of causing a variety of infections, including
bacteremia, meningitis, pneumonia, and peritonitis, partic-
ularly in immunocompromised hosts and patients with
underlying diseases [21]. Nosocomial outbreaks attributed
to disinfectant solutions, saline solutions, and diagnostic
tracers contaminated with this species have been described
[22, 23].
In patients with CF, an increasing prevalence of A.
xylosoxidans isolates has recently been reported [24–28],
but the clinical significance of A. xylosoxidans infection is
still unclear.
Because of the relevance of bacterial lung infections in
CF patients, the aims of our study were to: (1) evaluate the
frequency of A. xylosoxidans infections in a cohort of CF
patients, (2) investigate the antimicrobial sensitivity of
isolates, (3) establish possible clonal likeness among
strains, as well as to (4) elucidate possible clonal likeness
among strains isolated from the same patients during the
study period and (5) address a possible clinical relevance of
this infection on the general outcome of these patients.
Patients and methods
Study population
A retrospective chart review of microbiological samples
obtained from 300 CF patients (145 males and 155 females;
mean age 16.21 years; range 0.5–50 years) regularly
attending the Regional Referral Cystic Fibrosis Center of
Naples, Italy, was undertaken. Sputum samples were
collected during the period January 2004 to December
2008. CF was diagnosed on the basis of standard methods
(sweat chloride test above 60 mmol/l by pilocarpine and
two relevant CF transmembrane regulator mutations).
For each patient, data about anthropometric parameters,
pancreatic status, and the mean number of pulmonary
exacerbations requiring intravenous antibiotics during the
previous 12 months were obtained from our existing patient
database.
Patients over 6 years of age had at least one lung function
evaluation during each year of observation, as measured by
the forced expiratory volume in 1 s (FEV1), expressed as a
percentage of predicted values for the relevant age, sex,
ethnic background, weight, and height.
Despite the central role that pulmonary exacerbations
play in CF patient care and research, no standardized
definition about pulmonary exacerbations exists. Some of
the characteristics most strongly associated with a pulmo-
nary exacerbation include increased cough, increased
sputum production, decreased exercise tolerance, decline
in weight-for-age percentile, reduced appetite, hemoptysis,
and new sounds on examination of the chest [29, 30]. In
our patients, pulmonary exacerbations were defined accord-
ing to these suggestions.
Sputum samples for microbiological studies were
obtained from each patient at least every 3 months at
clinical examinations. Patients infected by A. xylosoxidans
were characterized for age, age of acquisition of first
infection, co-infection, lung function, and death. Chronic
infection was defined as persistence of three positive
cultures for at least six consecutive months, intermittent
infection was defined as the presence of three non-
consecutive positive cultures per year, and sporadic
infection when less than three cultures were positive per
year [31]. Co-infection was defined as sputum culture
positive for more than one microorganism.
Isolates were defined as multidrug-resistant organisms
(MDROs) according to the most recent definition given by
the Centers for Disease Control and Prevention (CDC) [32].
In order to correlate chronic A. xylosoxidans infection
and chronic P. aeruginosa i n f e c t i o nt ol u n gf u n c t i o n ,
clinical features of chronically A. xylosoxidans-infected
patients (case group) were compared with those of
chronically P. aeruginosa-infected patients (control group);
thus, two groups were matched for age, gender, body
weight, FEV1,a n dP. aeruginosa infection status. A.
xylosoxidans had never been isolated from any patient of
the control group. Nutritional status was calculated as the
body mass index (BMI, kg/m
2). Data were compared for
the period from one year before to one year after the onset
of A. xylosoxidans infection. The t-test was used for the
analysis of continuous variables and Chi-square test was
used for categorical variables. A p-value of less than 0.05
was considered to be statistically significant.
Processing of sputum samples, culture of microorganisms,
and phenotypic analysis
Sputum samples, obtained from all patients during the
s t u d yp e r i o d ,w e r em i x e dw i t he q u a lv o l u m e so f1 %
dithiothreitol before incubation at 37°C for 30 min. All
specimens were examined microscopically and plated on
several agar media, including MacConkey agar, CNA
agar, BCSA, and Sabouraud agar, at 37°C for 24 up to
72 h.
All isolates were identified by the Phoenix System
(Becton Dickinson); the API 20NE identification system
(bioMérieux) was used to confirm the identification of A.
xylosoxidans isolates.
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Analysis for 16S rDNA gene-based identification
To validate the phenotypic identification, a polymerase
chain reaction (PCR) assay was performed. DNA was
prepared by heating one or more colonies (picked from an
overnight growth plate) at 95°C for 15 min in 20 μl of lysis
buffer containing 0.25% sodium dodecyl sulfate and 0.05
NaOH. After lysis, 180 μl of sterile distilled water was
added to the lysis buffer.
The 16S rDNA gene (163 bp) was amplified using the
primers AX-F1 and AX-B1, respectively, for the target 5′
and 3′ ends of the 16S rDNA gene locus (AX-F1, sequence
5′-3′ GCAGGAAAGAAACGTCGCGGGT, nucleotide
positions 427–448; AX-B1, sequence 5′-3′ ATTTCA
CATCTTTCTTTCCG, nucleotide positions 576–595)
[10]. PCR was performed in a total volume of 100 μl
containing 0.5 γ/λ DNA, 25 mM MgCl2, 25 mM dNTPs,
1 μM concentration of each oligonucleotide primer, and
5U/μl Taq polymerase. After initial heating at 94°C for
1 min, 35 cycles of denaturation at 94°C for 1 min,
annealing at 56°C for 45 s, and extension at 72°C for
1 min were performed. The final extension step was at 72°C
for 10 min. Control strain (A. xylosoxidans ATCC 27061)
and negative control PCRs were employed for every
experiment.
Antimicrobial susceptibility test
To assess the sensitivity to aztreonam, piperacillin,
piperacillin–tazobactam, cefotaxime, cefepime, ceftazi-
dime, ciprofloxacin, levofloxacin, chloramphenicol, imi-
penem, meropenem, trimethoprim–sulfamethoxazole,
gentamicin, netilmicin, rifampin, and tetracycline, an
agar diffusion method (Kirby–Bauer) and the microbroth
dilution assay (Phoenix system) were used. A total of
five non-CF A. xylosoxidans isolates (one isolate per year
of study) was included for the antimicrobial susceptibility
analysis. These isolates were obtained from several
biological samples, i.e., sputum, blood, vascular catheter,
burn wound, and urine.
Interpretative criteria for susceptibility for all of the
methods used in the study were in accordance with Clinical
and Laboratory Standards Institute (CLSI) criteria [33].
PFGE genotyping
Isolates were grown overnight on nutrient agar and
suspended in SE buffer (75 mM NaCl, 25 mM EDTA, pH
7.5). The cell suspension (4 McFarland) was mixed with an
equal volume of 1.6% low-melting-point agarose, molded
into plugs at 4°C, and lysed with lysis buffer (1% N-lauryl
sarcosine, EDTA 0.5 M, pH 8.00), with the addition of
proteinase K [34]; the DNA inserts were digested with DraI
(Promega), at 37°C for 19 h. Macrorestriction fragments
were separated using CHEF DR III (Biorad) at 10°C for
20 h, with start time of 5 s and end-pulse time of 35 s, at a
field strength of 6 V/cm. A concatemer ladder of lambda
phage DNA was used as a size marker. Fragment patterns
were compared according to Tenover’s criteria [35].
Besides, to interpret the molecular patterns, a dendrogram
was generated using Phoretix 1D Pro software (TotalLab).
To examine whether each patient persistently carried the
same A. xylosoxidans strain during the study period, from
two up to six isolates for each patient per year were
analyzed. A total of five non-CF A. xylosoxidans isolates
(one isolate per year of study) was included for the pulsed-
field gel electrophoresis (PFGE) analysis (obtained from
sputum, blood, vascular catheter, burn wound, and urine).
Results
Prevalence of isolates, chronically infected patients,
and co-infection with other microorganisms
Over the study period, a total of 5,315 sputum samples
were obtained from 300 patients. In Table 1, the total
number of isolates and number and percentage of the total
MDROs for each type of bacteria isolated in the study
period are reported.
A total of 276 isolates of A. xylosoxidans were recovered
and the results obtained by PCR assay were in agreement
with biochemical identification. A total of 53 patients
(17.6%) had at least two positive cultures for A. xylosox-
idans (24 males and 29 females, mean age 21.14 years,
range 6.25–48 years).
Table 1 Distribution (number and percentage) of the total multidrug-
resistant Gram-negative isolates during the study period
Total strains MDROs
No. % No. %
P. aeruginosa 2,340 59 457 19.5
S. maltophilia 750 18.9 176 23.4
A. xylosoxidans 276 6.9 62 22.4
B. cepacia 20 0.5 5 25
B. cenocepacia 550 13.8 387 70.3
B. stabilis 15 0.3 7 46.6
B. vietnamiensis 10 0.2 4 40
B. gladioli 3 0.07 ––
3,964 1,098 27.6
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infected patients (3 males and 3 females, mean age
11.5 years, range 9.9–21.4 years, mean colonization period
2.7 years) and were co-colonized by P. aeruginosa (mean
age at P. aeruginosa chronic infection 9.5 years, range 6–
13.7 years).
There were 7/53 (13.2%) patients considered with
intermittent infection by A. xylosoxidans (4 males and 3
females, mean age 30 years, range 21–51.9 years), while
there were 40/53 (75.5%) patients with sporadic infection
(18 males and 22 females, mean age 17.3 years, range 6.2–
35.7 years).
In general, co-infection by P. aeruginosa was found in
17/53 patients (32%) with sporadic/intermittent infection.
Particularly, 4/17 patients were co-infected by A. xylosox-
idans and P. aeruginosa, while 13/17 patients were co-
infected by A. xylosoxidans, P. aeruginosa, and other
microorganisms (S. aureus, H. influenzae, B. cepacia
complex, S. maltophilia, Proteus mirabilis, C. indologenes,
and A. fumigatus). Co-infection by Candida albicans was
found in 23/53 patients (43.3%).
The correlation among clinical features of chronically A.
xylosoxidans-infected patients (case group) and chronically
P. aeruginosa-infected patients (control group) was carried
out. As shown in Table 2, no significant difference was
found between case and control groups in relation to the
parameters considered.
Antimicrobial susceptibility test
Considering one isolate per patient, and considering that
each isolate showed the same antimicrobial profile during
the whole study period, 10/53 (18.8%) A. xylosoxidans
isolates were multidrug-resistant, showing resistance to
aztreonam (minimum inhibitory concentration MIC>
16 μg/mL), to cephalosporins, including cefepime (MIC>
16 μg/mL), ceftazidime (MIC>16 μg/mL), and cefotaxime
(MIC>32 μg/mL), to carbapenem (imipenem MIC>8 μg/
mL; meropenem MIC>8 μg/mL), to aminoglycosides
(gentamicin MIC>8 μg/mL), to ciprofloxacin (MIC>
2 μg/mL), to levofloxacin (MIC>4 μg/mL), and trimetho-
prim–sulfamethoxazole (MIC>2/38 μg/mL). On the other
hand, these ten isolates were sensitive to piperacillin (MIC
<4 μg/mL) and piperacillin–tazobactam (MIC<4/4 μg/
mL). All six chronically infected patients carried multidrug-
resistant isolates.
Forty-three patients carried isolates that were resistant to
aztreonam and sensitive to ceftazidime (MIC<8 μg/mL), to
carbapenem (imipenem MIC<2 μg/mL; meropenem MIC<
1 μg/mL), to ciprofloxacin (MIC<2 μg/mL), to levoflox-
acin (MIC<24 μg/mL), trimethoprim–sulfamethoxazole
(MIC<0.5/9.5 μg/mL), and chloramphenicol (MIC<
16 μg/mL). Also, these isolates were sensitive to piper-
acillin and piperacillin–tazobactam. Table 3 shows the
results of the antimicrobial susceptibility testing of A.
xylosoxidans isolates (n=53), besides the antimicrobial
profile of P. aeruginosa co-infected isolates (n=23).
Genome macrorestriction analysis
PFGE analysis (Figs. 1 and 2) showed the possibility to
group into clusters more than half of the strains (39/53;
73.58%). Seven major clusters were found (A–Gc l u s t e r s ) .
Strains grouped in each cluster showed a diversity
(distance level) of less than 10% (or homology level
>90%). Cluster A groups 9/53 strains, cluster B groups 3/
53 strains, cluster C groups 8/53 strains, cluster D groups
3/53 strains, cluster E groups 4/53 strains, cluster F groups
6/53 strains, and cluster G groups 6/53 strains. The other
14 strains showed a unique macrorestriction profile.
Sequential strains obtained in the study period from the
same patient showed identical macrorestriction profiles.
Discussion
The survival of CF patients is now increased (median age
>30 years) and, consequently, new pathogens have emerged
in the CF lung. As underlined by Tan et al. [9], the
intensive use of antibiotics may be one factor that increases
the likelihood of opportunistic infections with resistant
microorganisms.
We found in our cohort a high prevalence of A.
xylosoxidans infection (17.6% of the 300 enrolled
patients), if the data are compared with those of Magni
et al. [36], where a prevalence infection of 8.8% is
indicated (enrolled patients=450). Our data indicate a
high prevalence of infection also if they are compared
with European studies, such as that conducted by
Kanellopoulou et al. [27], where the authors show a
prevalence of A. xylosoxidans infection of 12.6% (enrolled
patients=71). The reason for this high prevalence in our
population is likely linked to a higher mean age of
patients.
The clinical impact of A. xylosoxidans infection is not
clear, as well as its lung colonization. Our data are not
indicative of increased morbidity linked to this infection/
colonization. Besides, our study design does not indicate
effects on the clinical status from chronic/intermittent/
sporadic A. xylosoxidans infection. We found no significant
difference in the FEV1 and BMI comparing chronically A.
xylosoxidans infected patients with chronically P. aerugi-
nosa infected patients during the study period. The mild
lower mean FEV1 observed in patients with chronic A.
xylosoxidans infection could also have been influenced by
other covariates, such as diabetes.
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co-colonized also by P. aeruginosa and, generally, 43.3%
of patients present also P. aeruginosa infection. In the study
of Van Daele et al. [37], there is indicated the strong
tendency by A. xylosoxidans to install itself in a lung
already infected by P. aeruginosa. But, in this study, only
patients colonized by P. aeruginosa were enrolled. Our data
also indicate this tendency by A. xylosoxidans but,
differently from the study of Van Daele et al., our
population also included patients not co-colonized by P.
aeruginosa (56.6%; 30 non-co-infected by P. aeruginosa/
53). Thus, we can affirm that A. xylosoxidans can infect a
lung also not previously colonized by P. aeruginosa.
In our cohort, none of the patients had a transplantation
during the study. About 10% of patients (5/53) died in the
examined period, two were chronically infected by A.
xylosoxidans and all of these five patients were chronically
infected by P. aeruginosa. However, it is not possible to
link these deaths to A. xylosoxidans infection/colonization.
Because of the emergence of new Gram-negative micro-
organisms among CF patients, bacterial misidentification is
especially problematic and presents a challenge to effective
infection control in CF, to antimicrobial therapy, and to
patient prognosis.
There is evidence of weakness of commercial systems
for the phenotypic identification of non-fermentative Gram-
negative bacteria recovered from CF patients. Saiman et al.,
in a report from 2001 [26], indicated that, in a group of 106
isolates obtained from 78 patients from 49 CF centers in the
United States and all identified as A. xylosoxidans, 89%
were correctly identified, whereas 11% were misidentified;
thus, ten isolates were found to be P. aeruginosa, one
isolate S. maltophilia, and one B. cepacia complex. We
have demonstrated that the phenotypic identification,
carried out by Phoenix and API 20NE systems, was
confirmed by PCR analysis.
As a consequence of the increasing use of antibiotics
concomitant to acute pulmonary exacerbations in CF
patients due to P. aeruginosa infection, A. xylosoxidans as
well as other non-fermentative Gram-negative bacteria are
showing growing drug resistance. Our data support this
evidence because of frequent previous colonization with P.
aeruginosa.
It is well known that, for most of the non-lactose
fermenting, Gram-negative rods, the disk diffusion antibio-
gram is not validated by the CLSI. In fact, there are several
interpretation problems, such as unclear inhibition zone
borders. Consequently, in the present study, a microbroth
Table 2 Clinical features of chronically A. xylosoxidans-infected patients (case group) compared with the control group
Chronically infected patients
by A. xylosoxidans (n=6)
Chronically infected patients
by P. aeruginosa (n=6)
p-
value
−1 year Time0 +1 year −1 year Time0 +1 year
Mean age 10.5 11.5 12.5 11.1 12.1 13.1 >0.05
BMI 16.9 17.8 18.2 16.8 17.3 17.4 >0.05
Mean FEV1 (%) (range) 66.5%
(33.6–86%)
62%
(33.6–79%)
61.7%
(34.8–76%)
63.%
(45.2–99%)
63.2%
(38.4–99%)
63.7%
(38.4–97%)
>0.05
P. aeruginosa
co-colonization
(no. of patients)
666–––
CFRD (no. of patients) 1 1 3 1 3 4 >0.05
CFRD=cystic fibrosis-related diabetes
Table 3 Percentage of A. xylosoxidans (AX; n=53) and P. aeruginosa*( P A ;n=23) isolates resistant to the antibiotics tested
Antibiotics
ATM FEP CTX CAZ CIP CHL GEN IPM LVX MEM NET PIP TZP TET SXT
AX 100 28 28 18.8 18.8 18.8 37 18.8 18.8 18.8 41 0 0 73 18.8
PA 26 21 82 17 52 91 65 47 56 43 43 43 26 98 100
*Isolates recovered in co-infection with Achromobacter xylosoxidans
ATM=aztreonam; FEP=cefepime; CTX=cefotaxime; CAZ=ceftazidime; CIP=ciprofloxacin; CHL=chloramphenicol; GEN=gentamicin; IPM=
imipenem; LVX=levofloxacin; MEM=meropenem; NET=netilmicin; PIP=piperacillin; TZP=piperacillin–tazobactam; TET=tetracycline; SXT=
trimethoprim–sulfamethoxazole
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found between the two methods.
With the emergence of antimicrobial resistance of new
pathogens, the scenario has changed with respect to the
availability and susceptibility of antimicrobial agents. In our
study, about 20% of A. xylosoxidans isolates showed a
multidrug-resistant profile. This percentage of isolates was
resistant to aztreonam, cephalosporins, including cefepime,
ceftazidime, and cefotaxime, to carbapenem, aminoglyco-
sides, quinolones, and trimethoprim–sulfamethoxazole.
These same isolates were sensitive to piperacillin with or
without tazobactam. Ceftazidime, carbapenems, quinolones,
and trimethoprim–sulfamethoxazole, besides piperacillin
and piperacillin–tazobactam, were active against non-
multidrug-resistant isolates. A. xylosoxidans isolates recov-
ered from non-CF patients were resistant to molecules such
as ceftazidime, carbapenems, and levofloxacin. This finding
indicates that isolates of A. xylosoxidans can be resistant to
many antimicrobial agents, independently from the study
population.
Currently, reports for patient-to-patient spread are con-
troversial. Several studies rule out the possibility of A.
xylosoxidans by inter-human contacts, or at least they
indicate little evidence of person-to-person transmission,
Cluster A 
Cluster C 
Cluster E 
Cluster G 
Cluster B 
Cluster D 
Cluster F 
Fig. 2 Phylogenetic analysis of digitized PFGE DraI profiles of A. xylosoxidans analyzed in the study. Cluster analysis is based on the percentage of
distance index. The numbers indicate the strains in the study and the letters indicate the clusters
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Fig. 1 PFGEanalysisofrepresentativestrainsofA. xylosoxidans.T h enumbers indicate the strains in the study. Molecular size marker (a concatemer
ladder of lambda phage DNA) was run in lane ST. Sizes are indicated in kilobases
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PFGE indicates that more than half of A. xylosoxidans can
be grouped into seven different clusters, suggesting the
possibility of patient-to-patient transmission.
The results of PFGE have been interesting for several
reasons. First, all six chronically infected patients carried
strains of two different clusters (four strains of cluster A and
two strains of cluster C); besides, among five cases of death,
one patient carried strain A and four patients carried strains
withauniquemacro-restrictionprofile.Atlast,anystrainwith
a unique macro-restriction profile was considered to be an
MDRO, whereas four strains of clone A, two of clone B, and
four of clone C were considered to be MDROs.
These results are supported by a recent study of
Kanellopoulou et al. [27], where the authors indicated five
CF patients colonized by genetically related strains. Our
results certainly suggest a common source of contamination
and this is highly probable because of the frequent social
contacts that occur among patients of a single care center.
It is very interesting to note that, in our study, restriction
patterns were obtained by both DraI and by SmaI.
Restriction endonuclease SmaI generated a lower number
of bands with respect to those generated by DraI (data not
shown). Consequently, DNA cleavage by this endonuclease
was characterized by increased sensitivity.
In conclusion, the results of the present study can
represent a further step toward the understanding of the
epidemiology of these microorganisms and of a possible
correlation between the microbiological data and clinical
outcomes of CF patients.
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